(Q43049155)

English

Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.

scientific article published in April 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yoshiyasu Karino

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Jouji Toyota

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Masaaki Sugawara

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kayo Miyazaki

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yasuaki Kuwata

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Katsu Yamazaki

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Takahiro Sato

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Takumi Ohmura

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Takashi Matsushima

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 April 2003

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

404-410

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Clinical significance of hepatitis C virus genotypes.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Clinical significance of hepatitis C virus genotypes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2003.03009.X

21 January 2018

Identifiers

10.1046/J.1440-1746.2003.03009.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43049155&oldid=1590666337"